Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) is a publicly traded Healthcare sector company. As of October 29, 2026, MRVI trades at $8.29 with a market cap of $1.27B and a P/E ratio of -14.10. MRVI moved -0.47% today. Year to date, MRVI is +123.22%; over the trailing twelve months it is +175.57%. Its 52-week range spans $1.67 to $9.42. Analyst consensus is buy with an average price target of $7.88. Rallies surfaces MRVI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Maravai LifeSciences unit TriLink wins new China CleanCap patent for cap analog compounds: TriLink BioTechnologies won a China patent covering CleanCap cap analog compounds used to make 5’-capped RNAs, as well as related RNAs, cells and pharmaceutical products.
| Metric | Value |
|---|---|
| Price | $8.29 |
| Market Cap | $1.27B |
| P/E Ratio | -14.10 |
| EPS | $-0.53 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.42 |
| 52-Week Low | $1.67 |
| Volume | 1.05M |
| Avg Volume | 0 |
| Revenue (TTM) | $208.78M |
| Net Income | $-136.08M |
| Gross Margin | 34.89% |
6 analysts cover MRVI: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.88.